Empress Royalty Corp. (TSXV:EMPR)

Longboard Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Sep 30, 2021
Net Income	1.98	1.01	-2.93	-3.38	-3.2	-2.91
Depreciation & Amortization	1.77	1.61	1.18	0.73	0.07	-
Asset Writedown & Restructuring Costs	-	-	0.73	-	-	-
Loss (Gain) From Sale of Investments	-	-	-	-	0.04	0.05
Stock-Based Compensation	0.28	0.42	0.62	0.74	0.77	0.62
Other Operating Activities	1.74	1.56	0.89	1.4	0.02	-
Change in Accounts Receivable	-0.91	-1.29	-0.5	-0.18	-0	-0
Change in Accounts Payable	-0.05	0.2	0.35	-0.28	0.17	-0.03
Change in Other Net Operating Assets	-0.02	0.03	-0.13	0.02	-0	-0.05
Operating Cash Flow	4.78	3.54	0.21	-0.94	-2.13	-2.31
Operating Cash Flow Growth	1076.99%	1565.55%	-	-	-	-
Sale (Purchase) of Intangibles	-	-5	-	-1	-15.08	-13.92
Investment in Securities	-	-	-	-	0.1	0.13
Investing Cash Flow	-	-5	-	-1	-14.97	-13.79
Long-Term Debt Issued	-	5	3.44	-	-	-
Total Debt Issued	-	5	3.44	-	3.3	-
Long-Term Debt Repaid	-	-3.46	-3.99	-1.37	-	-
Net Debt Issued (Repaid)	-3.87	1.54	-0.55	-1.37	3.3	-
Issuance of Common Stock	-	-	0.98	1.98	15.29	19.3
Other Financing Activities	-0.18	-0.31	-0.17	-	-0.94	-1.18
Financing Cash Flow	-4.05	1.23	0.27	0.61	17.64	18.12
Foreign Exchange Rate Adjustments	-0.02	0.01	-0.01	0.01	0.18	-
Net Cash Flow	0.71	-0.22	0.46	-1.32	0.71	2.02
Cash Interest Paid	0.92	0.94	0.49	0.57	-	-
Levered Free Cash Flow	1.92	-3.5	0.12	-2.09	-	-14.63
Unlevered Free Cash Flow	2.84	-2.62	0.97	-1.21	-	-14.63
Change in Net Working Capital	1.54	1.28	0.21	0.45	-	0.08

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.